Is Inalisate (Iheli) a Roche pharmaceutical product and its market positioning?

Inavolisib is an oral small molecule targeted drug developed by Roche Pharmaceuticals. It is mainly used for patients with breast cancer related to PIK3CA gene mutations. Its mechanism of action is to selectively inhibit PI3Kα isoform, block tumor cell proliferation and survival signaling pathways, thereby inhibiting tumor growth. As an innovative drug developed by Roche, inalisate has undergone clinical trials in many countries and regions around the world and has gradually been approved for marketing. It is mainly aimed at the precise treatment needs of patients with specific gene mutations.

In the domestic market, Inalise is already on the market, but it has not yet been included in the medical insurance system. The current common specifications include 3mg7tablets4boards and 9mg7tablets4boards. Due to the short time the drug has been on the market, its retail price is about 30,000 yuan. Patients must follow the doctor's advice for genetic testing when using it to ensure that it meets the indications for PIK3CA mutation and obtain the best therapeutic effect.

In overseas markets, the original drug of Inariside is sold at a higher price, which may reach more than 200,000 yuan per box. The specific price fluctuates due to exchange rates and regional policies. At present, there are no generic drugs on the market, so the main way for patients to obtain drugs still relies on the supply channels of original drugs. The high overseas prices are significantly different from the domestic market, which also reflects the impact of innovative drugs in terms of research and development costs, clinical verification and market access.

Generally speaking, as an innovative targeted drug of Roche Pharmaceuticals, inaliside has a clear market positioning in the field of precision treatment, mainly targeting patients with PIK3CA mutated breast cancer. Domestic patients should combine genetic testing and doctor's guidance when using it, choose regular channels to purchase, and pay attention to drug prices and medical insurance policy trends. At the same time, since there are no generic drugs on the market yet, patients need to make adequate planning and evaluation in terms of medication cost and accessibility to ensure the safety and effectiveness of treatment.

Reference link:https://www.drugs.com